Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/15/21
End: 08/26/23
Due: 08/26/24
Phase: N/A
Priority: Normal
Start: 06/01/23
End: 06/30/25
Due: 06/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test | NCT05282797 | Anebulo Pharmaceuticals | user2@example.com | None | 2021-12-15 | 2023-08-26 | 2024-08-26 | - | - | 2025-07-14 |
| Observational Study of THC Concentrations in Acute Cannabinoid Intoxication | NCT06017622 | Anebulo Pharmaceuticals | user2@example.com | None | 2023-06-01 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |